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Objective: To study the effect and mechanism of the dysfunction of CD4+ T cells in the
disease process of chronic cardiac failure (CHF).
Methods: According to different group technologies, 100 CHF patients were divided
into the following groups: ischemia group and non-ischemia group, heart function Ⅲ–Ⅳ
group and heart function Ⅰ–Ⅱ group, event group and non-event group, and 50 healthy
volunteers were included in the control group. Real-time PCR was used to detect tran-
scription factors T-bet and GATA-3 of Th1 and Th2; ﬂow cytometry was applied to
determine the ratio of Th17 and Treg cells; ELISA was employed to test cytokines IFN-g,
IL-4, IL-17 and IL-10 of peripheral blood Th1, Th2, Th17 and Treg cells, respectively;
ultrasonic cardiogram was used to exploit to LVEF and LVEDd; and electrochemilu
minescene immunoassay was used to examine plasma BNP. The differences of all in-
dexes of all groups were analyzed and the correlation between CD4 T cells and clinical
indexes was analyzed by Pearson correlation analysis.
Results: As compared to the control group, the transcription factors T-bet and GATA-3
of Th1 and Th2, the ratio of cytokines Th17 and IFN-g, cytokines IL-17, T-bet/GATA-3,
IFN-g/IL-4, Th17 cells/Treg cells, IL-17/IL-10 of the ischemia group and non-ischemia
group, heart function Ⅲ–Ⅳ group and heart function Ⅰ–Ⅱ group, event group and non-
event group were all increased signiﬁcantly, while their transcription factor GATA-3
of Th2, cytokines IL-4, Treg cells ratio, cytokines IL-10 were decreased obviously.
The differences showed statistical signiﬁcance (P < 0.05). The increase or decrease of the
partial CD4+ T cells of the ischemia group, heart function Ⅲ–Ⅳ group and event group
was more distinctly. The results of Pearson correlation analysis showed that IFN-g and
IL-17 were signiﬁcantly positively correlated with LVEDd and BNP, IL-4 and IL-10
were also signiﬁcantly positively correlated with LVEF, but correlated negatively with
BNP, and IL-17 was negatively correlative with LVEF.
Conclusions: There was a correlation between CHF and the dysfunction of CD4+ T cells
showing immune activation phenomenons of deviations from the Th1/Th2 balance to-
wards Th1 and from the Th17/Treg balance towards Th17, which was also related to the
types, severity and prognosis of the disease.1. Introduction
Chronic cardiac failure (CHF) is a clinical syndrome with a
complicated pathogenesis, which is the severe stage of all kindsof cardiovascular diseases [1,2]. In recent years, researchers have
found pathological immune responses against myocardial cells
in CHF patients. After myocardial injury, auto-antigen acti-
vated immune cells and inﬂammatory cytokines are released
and participate in the incidence and development of heart failure
[3–5]. As an important part of the immune system, cell immune
plays an important role in eliminate pathogenic bacteria and
cancer cells [6]. T cells play a critical role in cell immune
including the helper T cells of CD4 and cytotoxic T cells of
CD8 [7]. Helper T cells have attracted much attention in
recent years due to their anti-tumor effect which has been
proved to be as strong as that of cytotoxic T cells of CD8 [8].icle under the CC BY-NC-ND license (http://
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and Tfh. Th1 cells secrete IFN-g, TNF-a, IL-2 and so on and
mediate immune responses of antiviral cells and intracellular
bacteria [9]. Th2 cells secrete IL-4, IL-5, IL-13 and so on and
mediate immune responses of anti-parasitism extracellular mi-
crobial [10]. Th17 cells secrete IL-17 and mediate inﬂammatory
reactions such as rheumatoid arthritis [11]. Treg cells secrete IL-
10 and TGF-b and also mediate immunosuppression [12]. Tfh
cells secrete IL-21 and mediate humoral immune responses by
assisting B cells [13]. All cell subsets maintain a balance stage.
The unbalance of CD4+ T cells participates in the occurrences
and developments of various autoimmunity diseases such as
systemic lupus erythematosus [14], cancers [15], infections [16]
and so on. Over the years, the correlations between immune
responses with the pathogenesis of CHF have attracted
extensive attention, but there are a few studies analyzing CHF
patients and CD4+ T cells systematically. This study aimed to
analyze the relationship between the dysfunction of CD4+ T
cells with the pathogenesis of CHF by analyzing the CD4+ T
cells in CHF patients mainly including the Th1/Th2 balance
and Th17/Treg balance and their cytokines levels and
collecting the clinical data of those patients.
2. Materials and methods
2.1. Clinical data
A total of 100 cases treated in the Afﬁliated Hospital of
Guizhou Medical University from July 2014 to February 2015
were chosen as the study subjects. All patients were all deﬁnitely
diagnosed in accordance with symptoms, signs, medical his-
tories, experimental examinations and imaging tests. Patients
with combined immune system diseases, endocrine system dis-
eases such as thyroid diseases, acute or chronic infections, acute
or chronic inﬂammatory diseases, rheumatic diseases, acute
myocardium infarction and unstable angina pectoris in recent
period, recent histories of using drug such as corticosteroids
which affected immune responses or hepatic and renal
dysfunction were excluded. Among those 100 cases, 63 of them
were males and 37 were females. Their ages range from 56 to 80
years. The average age was (67.82 ± 12.27) years. Patients were
divided into different subgroups by different group technologies.
Based on the different protopathy, they were divided into the
ischemia group and non-ischemia group. There were 75 cases in
the ischemia group in which 48 cases were males and 27 were
females aging from 56 to 78 years with an average age of
(67.12 ± 12.41) years. There were 25 cases in the non-ischemia
group in which 15 cases were males and 10 were females aging
from 58 to 80 years with an average age of (68.03 ± 12.30)
years. According to the cardiac function grade of New York
Heart Academy (NYHA), patients were divided into the heart
function Ⅲ–Ⅳ group and heart function Ⅰ–Ⅱ group. There were
62 cases in the heart function Ⅲ–Ⅳ group in which 41 were
males and 21 were females aging from 58 to 79 years with an
average age of (68.21 ± 11.69) years. There were 38 cases in the
heart function Ⅰ–Ⅱ group in which 22 were males and 16 were
females aging from 56 to 80 years with an average age of
(67.09 ± 13.15) years. After a year of follow-up, according to the
presence or absence of cardiovascular event, patients were
divided into the event group and non-event group. There were
18 cases in the event group in which 11 were males and 7 were
females aging from 60 to 80 years with an average age of(68.87 ± 12.08) years, while there were 82 cases in the non-
event group in which 52 were males and 30 were females ag-
ing from 56 to 77 years with an average age of (67.31 ± 12.26)
years. Meanwhile, 50 healthy volunteers were regarded as the
control group. In the control group, 28 of them were males and
22 were females whose ages ranged from 55 to 80 years. The
average age was (67.29 ± 13.30) years. Differences of ages and
genders showed no statistical signiﬁcance. The study was
approved by the Hospital's Ethics Committee. All chosen sub-
jects signed a informed consent.
2.2. Detection methods
2.2.1. Transcriptional factors Th1 and Th2 detected by
real-time PCR
PCR primers were referred to the related study [17], and
reverse transcription kits were purchased from Promega
(USA). Trizol reagent produced by Invitrogen was used to
extract RNA. Heat-start ﬂuorescence PCR kits were bought
from Gibco-BRL (USA). 7300 Real-time PCR System was
provided by ABI Cooperation (USA). Five milliliters peripheral
venous blood of each chosen cases were drawn and ethyl-
enediaminetetraacetic acid (EDTA) was used for anti-
coagulation. Peripheral blood mononuclear cell (PBMC) was
separated routinely and then the total mRNA was extracted and
stored at low temperature in accordance with the instruction of
the kits. The condition for the synthesis of DNA was 50 min at
42 C, 5 min at 95 C. Fluorescence signals were collected by
three-step reaction. The relative expression quantities of the
transcription factors T-bet and GATA-3 of Th1 and Th2 could
be obtained with 7300 Real-time PCR System.
2.2.2. The ratio of Th17 and Treg cells tested by ﬂow
cytometry
Anti-human CD8 antibody marked by FITC and anti-human
CD3 antibody marked by PC5 were added into the stand-by cells
and incubated for 30 min at normal atmospheric temperature
without sunlight and then washed by PBS. After that, they were
involved in a ﬁxation reaction with stationary liquid for 20 min
at normal atmospheric temperature without sunlight. Then, the
supernate was cleared out and they were washed with PBS
again. After adding membrane rupture reagent, the supernate
was eliminated by centrifugation and cytokines were dyed. Next,
IL-17 marked by PE was added. The same control antibodies
were added into the control group for incubation for 30 min at
normal atmospheric temperature without sunlight and then it was
washed by PBS. Finally, they were ready for detection. The ratio
of Th17 was tested by FACS-CALIBUR ﬂow cytometry pro-
duced by BD Compang (USA).
Anti-human CD127 monoclonal antibody marked by PE,
anti-human CD4 monoclonal antibody marked by FITC and
anti-human CD25 monoclonal antibody marked by PC5 were
added into the stand-by cells, while the same antibodies were
added into the control tubes. They were incubated for 20 min at
normal atmospheric temperature without sunlight and then
washed by PBS. Then, red blood cell lysate was added and they
were incubated again at normal atmospheric temperature without
sunlight for 10 min. After centrifugation, the supernate was
removed and they were ﬁxed with stationary liquid and punched
by membrane rupture reagent. Foxp3 antibody marked by PE
was added in them. Also, the same antibody was added into the
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atmospheric temperature without sunlight and then washed by
PBS. Eventually, they were ready for detection. The ratio of
Treg cells was examined by FACS-CALIBUR ﬂow cytometry
produced by BD Compang (USA).
2.2.3. Peripheral blood cytokines determined by ELISA
Six milliliters peripheral blood was extracted and centrifuged
to separate serum. ELISA was used to determine peripheral
blood IFN-g, IL-4, IL-17 and IL-10. All kits were bought from
BD Company (USA).
2.2.4. Clinical indexes
PHILIPS IE 5500 color ultrasonic tester was implied to test the
left ventricular ejection fractions (LVEF) and left ventricular
end-diastolic diameter (LVEDd) with the long axis view of the left
heart near the sternum as the section and a transducer frequency of
2–4 MHz. Electrochemilu minescene immunoassay method was
employed to test the plasma brain natriuretic peptide (BNP).
2.3. Statistical management
SPSS19.0 statistic software was used for analysis. Compar-
isons in multiple groups were analyzed by variance analysis.
Comparisons between two groups were tested by SNK-q test.
Pearson correlation analysis was also used. The inspection level
a was 0.05.
3. Results
3.1. Comparison of the CD4 T cell subsets between CHF
ischemia group and non-ischemia group and the control
group
The transcription factor T-bet of Th1, cytokines IFN-g, the
ratio of Th17, cytokines IL-17, T-bet/GATA-3, IFN-g/IL-4,
Th17 cells/Treg cells, IL-17/IL-10 of the ischemia group and
non-ischemia group were all signiﬁcantly higher than those of
the control group, while their transcription factor GATA-3 of
Th2, cytokines IL-4, Treg cells ratio, cytokines IL-10 were
obviously lower. The differences were statistically signiﬁcant
(P < 0.05). Besides, the cytokines IFN-g of Th1, cytokines IL-
17 of Th17, T-bet/GATA-3, Th17 cells/Treg cells, IL-17/IL-10
of the ischemia group were all distinctly higher than those of
the non-ischemia group, while its cytokines IL-4 of Th2 and
cytokines IL-10 of Treg cells were evidently lower than those of
the non-ischemia group. The differences were also statistically
signiﬁcant (P < 0.05) (Table 1).
3.2. Comparison of the CD4 T cell subsets between CHF
heart function Ⅲ–Ⅳ group and heart functionⅠ–Ⅱ group
and the control group
The transcription factor T-bet of Th1, cytokines IFN-g, the
ratio of Th17, cytokines IL-17, T-bet/GATA-3, IFN-g/IL-4,
Th17 cells/Treg cells, IL-17/IL-10 of the heart function Ⅲ–Ⅳ
group and heart functionⅠ–Ⅱ group were all signiﬁcantly higher
than those of the control group, while their transcription factor
GATA-3 of Th2, cytokines IL-4, Treg cells ratio, cytokines IL-
10 were obviously lower. The differences were statistically
signiﬁcant (P < 0.05). Moreover, the cytokines IFN-g of Th1,cytokines IL-17 of Th17, T-bet/GATA-3 and Th17 cells/Treg
cells of the heart function Ⅲ–Ⅳ group were all distinctly higher
than those of the heart functionⅠ–Ⅱ group, while its cytokines IL-
4 of Th2 and the ratio of cytokines Treg cells were evidently
lower. The differences were also statistically signiﬁcant
(P < 0.05) (Table 2).
3.3. Comparison of the CD4 T cell subsets between CHF
event group and non-event group and the control group
The transcription factor T-bet of Th1, cytokines IFN-g, the
ratio of Th17 cells, cytokines IL-17, T-bet/GATA-3, IFN-g/IL-
4, Th17 cells/Treg cells, IL-17/IL-10 of the event group and
non-event group were all signiﬁcantly higher than those of the
control group, while their transcription factor GATA-3 of Th2,
cytokines IL-4, Treg cells ratio, cytokines IL-10 were all obvi-
ously lower. The differences were statistically signiﬁcant
(P < 0.05). In addition, the cytokines IFN-g of Th1, cytokines
IL-17 of Th17, T-bet/GATA-3, Th17 cells/Treg cells and IL-17/
IL-10 of the event group were all distinctly higher than those of
the non-event group, while its transcription factor GATA-3 of
Th2, cytokines IL-4, the ratio of cytokines Treg cells and cy-
tokines IL-10 of Treg were evidently lower. The differences
were also statistically signiﬁcant (P < 0.05) (Table 3).
3.4. The correlation analysis between the CD4 T cell
subsets of CHF patients and clinical indexes
Pearson correlation analysis revealed that there was a strong
positive correlation among IFN-g and LVEDd BNP, IL-4 was
signiﬁcantly positively correlated with LVEF but negatively
correlated with BNP, IL-17 was positively correlative with
LVEDd and BNP but negatively correlated with LVEF, and IL-
10 was also signiﬁcantly positively correlated with LVEF but
negatively correlated with BNP (Table 4).
4. Discussion
CHF can be caused by various heart diseases such as coro-
nary heart disease and hypertension. CHF appears in the later
stage of heart diseases which was mainly characterized by heart
failure. Due to the weak myocardial contractility of CHF pa-
tients, the cardiac output reduces and the normal metabolism
cannot get satisﬁed, which leads to the short of tissues and or-
gans infusion [18]. The incidence rate of CHF maintains 0.9%–
2%, and the incidence rate could increase to over 10% among
patients over 70 years old. With the improvement of the ﬁrst
and second levels of heart diseases prevention, aggravation of
astogeny and the perfection of the treatment of coronary
events, the incidence rate of CHF increases year by year [19].
Even though there is no new myocardial injury, CHF can still
develop by myocardial reconstitution. Studies suggest that the
prognosis of heart failure in its stable stage is similar to
common malignant tumors, but the survival rate of patients
with developing heart failure is lower than that of patients
with malignant tumors [20].
The pathogenesis of CHF is quite complicated which is
related to many factors such as heredity, immunity and
biochemistry. It has been conﬁrmed that the incidence and
development of CHF is related to the neuroendocrine activation.
The neuroendocrine activation of angiotensin converting
Table 1
Comparison of the CD4 T cell subsets between CHF ischemia group and non-ischemia group and the control group.
CD4 T cell subset Ischemia group (n = 75) Non-ischemia group (n = 25) The control group (n = 50)
Th1 Transcription factor T-bet 1.89 ± 0.45* 1.34 ± 0.26* 0.62 ± 0.18
Cytokines IFN-g (pg/mL) 76.21 ± 10.23*# 70.25 ± 7.78* 45.46 ± 5.20
Th2 Transcription factor GATA-3 0.35 ± 0.04* 0.50 ± 0.09* 1.21 ± 0.13
Cytokines IL-4 (pg/mL) 29.18 ± 3.89*# 35.72 ± 4.24* 44.30 ± 4.75
Th1/Th2 Transcription factor T-bet/GATA-3 5.40 ± 0.78*# 2.68 ± 0.54* 0.51 ± 0.06
Cytokines IFN-g/IL-4 2.61 ± 0.34* 1.97 ± 0.28* 1.03 ± 0.11
Th17 Th17 cells ratio (%) 2.46 ± 0.45* 2.08 ± 0.24* 0.47 ± 0.21
Cytokines IL-17 (pg/mL) 25.58 ± 3.09*# 21.05 ± 2.35* 14.28 ± 2.14
Treg Treg cells ratio (%) 4.01 ± 0.40* 5.12 ± 1.12* 8.55 ± 1.83
Cytokines IL-10 (pg/mL) 10.37 ± 2.09*# 13.23 ± 3.06* 22.65 ± 3.63
Th17/Treg Th17 cells/Treg cells 0.61 ± 0.06*# 0.41 ± 0.04* 0.05 ± 0.01
IL-17/IL-10 2.47 ± 0.25*# 1.59 ± 0.20* 0.63 ± 0.08
Compared with the control group, *P < 0.05; compared with the non-ischemia group, #P < 0.05.
Table 2
Comparison of the CD4 T cell subsets between CHF heart function Ⅲ–Ⅳ group and heart functionⅠ–Ⅱ group and the control group.
CD4 T cell subset Heart function Ⅲ–Ⅳ group (n = 62) Heart function Ⅰ–Ⅱ group (n = 38) The control group (n = 50)
Th1 Transcription factor T-bet 1.76 ± 0.42* 1.45 ± 0.25* 0.62 ± 0.18
Cytokines IFN-g 75.16 ± 8.76*# 69.26 ± 7.44* 45.46 ± 5.20
Th2 Transcription factor GATA-3 0.37 ± 0.04* 0.46 ± 0.06* 1.21 ± 0.13
Cytokines IL-4 30.31 ± 3.26*# 36.18 ± 4.18* 44.30 ± 4.75
Th1/Th2 Transcription factor T-bet/GATA-3 4.76 ± 0.66*# 3.15 ± 0.46* 0.51 ± 0.06
Transcription factor IFN-g/IL-4 2.48 ± 0.30* 1.91 ± 0.25* 1.03 ± 0.11
Th17 Th17 cell ratio 2.38 ± 0.38* 2.12 ± 0.30* 0.47 ± 0.21
Cytokines IL-17 25.16 ± 3.24*# 22.21 ± 2.64* 14.28 ± 2.14
Treg Treg cell ratio 3.62 ± 0.45*# 5.43 ± 1.24* 8.55 ± 1.83
Cytokines IL-10 11.09 ± 2.21* 12.15 ± 3.14* 22.65 ± 3.63
Th17/
Treg
Th17 cells/Treg cells 0.66 ± 0.08*# 0.40 ± 0.05* 0.05 ± 0.01
IL-17/IL-10 2.27 ± 0.31* 1.83 ± 0.22* 0.63 ± 0.08
Compared with the control group, *P < 0.05; compared with the heart functionⅠ–Ⅱ group, #P < 0.05.
Table 3
Comparison of the CD4 T cell subsets between CHF event group and non-event group and the control group.
CD4 T cell subset Event group (n = 18) Non-event group (n = 82) The control group (n = 50)
Th1 Transcription factor T-bet 1.80 ± 0.52* 1.40 ± 0.32* 0.62 ± 0.18
Cytokines IFN-g 79.89 ± 6.12*# 68.82 ± 9.16* 45.46 ± 5.20
Th2 Transcription factor GATA-3 0.33 ± 0.05*# 0.45 ± 0.05* 1.21 ± 0.13
Cytokines IL-4 26.28 ± 3.89*# 35.27 ± 4.20* 44.30 ± 4.75
Th1/Th2 Transcription factor T-bet/GATA-3 5.45 ± 0.69*# 3.11 ± 0.48* 0.51 ± 0.06
Cytokines IFN-g/IL-4 3.04 ± 0.34*# 1.95 ± 0.27* 1.03 ± 0.11
Th17 Th17 cell ratio 2.54 ± 0.42* 2.09 ± 0.34* 0.47 ± 0.21
Cytokines IL-17 25.89 ± 3.87*# 21.78 ± 2.45* 14.28 ± 2.14
Treg Treg cell ratio 3.21 ± 0.43*# 4.79 ± 1.35* 8.55 ± 1.83
Cytokines IL-10 10.02 ± 1.76*# 13.04 ± 2.36* 22.65 ± 3.63
Th17/Treg Th17 cells/Treg cells 0.79 ± 0.90*# 0.44 ± 0.05* 0.05 ± 0.01
IL-17/IL-10 2.58 ± 0.25*# 1.67 ± 0.21* 0.63 ± 0.08
Compared with the control group, *P < 0.05; compared with the non-event group, #P < 0.05.
Table 4
The correlation analysis between the CD4 T cell subsets and clinical
indexes.
CD4T cell subset LVEDd LVEF BNP
r P r P r P
IFN-g 0.332 0.000 −0.119 0.453 0.289 0.002
IL-4 −0.165 0.318 0.274 0.009 −0.238 0.049
IL-17 0.309 0.000 −0.346 0.000 0.260 0.018
IL-10 −0.098 0.761 0.253 0.032 −0.247 0.042
Yin-Hao Cai et al./Asian Paciﬁc Journal of Tropical Medicine 2016; 9(7): 682–687 685enzyme inhibitor and b-receptor inhibitor is used for symp-
tomatic treatment of CHF in clinical practice. Although it works
to some degree, the mortality of CHF still remains high. It has
been found in new studies that the activation of immune system
and the continuous inﬂammatory responses are related to the
occurrence of CHF [21,22]. The immune activation of CHF
mainly featured by the direct stimulation by cardiac antigens
or the exposure of cardiac antigens caused by cardiac antigens,
which launches the pathological immune responses and
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function.
The role CD4 T cells playing in the cellular immunity has
been a hot spot of research in recent years. By far, many subsets
of CD4 have been discovered such as Th1, Th2, Th17, Treg,
Tfh, etc. Th1 and Th2 were discovered earlier so that researches
about them were more mature. Th1 cells secrete IFN-g, TNF-a
and IL-2 and mediate the cellular immune responses of antiviral
or intracellular bacteria and pro-inﬂammatory cellular immune
responses; Th2 cells secrete IL-4, IL-5, IL-13 and others,
mediate immune responses and humoral immune responses of
anti-parasitic extracellular microbial and inhibit inﬂammatory
response. In normal healthy bodies, the ratio Th1/Th2 keeps
relative balance, so that the bodies' immune homeostasis can
also be maintained. The unbalance of Th1/Th2 can lead to a
series of diseases. The results of this study showed that as
compared to the control group the transcription factor T-bet of
Th1 and cytokines IFN-g of the ischemia group, non-ischemia
group, heart function Ⅲ–Ⅳ group, heart function Ⅰ–Ⅱ group,
event group and non-event group increased signiﬁcantly while
their transcription factor GATA-3 of Th2, cytokines IL-4
decreased distinctly. The evident increase of IFN-g/IL-4 and
T-bet/GATA-3 indicated that in CHF the balance of Th1/Th2
shifted towards Th1. The pro-inﬂammatory cellular immunity
caused by hyperfunction of Th1 could possibly be a mechanism
of pathologic autoimmune response of CHF. It is also found in
clinical researches that serum inﬂammatory factors in CHF pa-
tients present high expressions and the common-used drugs of
CHF such as b receptor inhibitor and statin work in the immune
system and adjust the Th1/Th2 balance [23]. The more signiﬁcant
the shift of Th1 is, the long the pathologic autoimmune response
of CHF patients persists, the more severe the degree is, the
obvious the decrease of the heart function shows and the
poorer the prognosis becomes.
Th17 is also a kind of subset of CD4 T cells, which is
different with Th1 and Th2. It mediates inﬂammatory responses
such as rheumatoid arthritis and immune system diseases by
secreting pro-inﬂammatory cytokines such as IL-17 [24]. IL-17
possesses strong pro-inﬂammatory effect which can stimulate
epithelial cells, endothelial cells, ﬁbroblasts and other cells to
release massive cytokines such as metalloproteinase-1, gran-
ulocyte colony-stimulating factor and IL-6 causing tissue in-
juries and inﬂammatory inﬁltration [25]. It is found that the high
expression of IL-17 in plaque or plasma of patients with coro-
nary heart disease is the main reason accounting for the unstable
plague and rupture [26]. Treg cells can inhibit the activation of
immune cells with the immunosuppressive and anergic effects
which are used to maintain immune tolerance. It was found
that the decrease of Treg cells played an important role in the
occurrence of autoimmune diseases and diseased related to
impaired immune balance [3]. Researchers on animals revealed
that the decrease of Treg cells would aggravate the
inﬂammatory responses of local injuries and increased the risk
of atherosclerosis [27]. Th17 and Treg cells have mutually
exclusive signal pathways in differentiations since they are all
from naive T cells. They inhibit each other. Under normal
circumstances, the immune system of the body is not activated
and the differentiation of Treg cells is normal and plays the
inhibitory role by different mechanisms, which can avoid body
injuries under the premise of the maintenance of immunity
homeostasis. The balance of Th17/Treg plays an important
role in the maintenance of immunity homeostasis, and theunbalance of Th17/Treg participates in the occurrences of
diseases such as infections, cancers and autoimmune diseases
[28,29]. It is found that the unbalance of Th17/Treg also plays
an important role in the incidence of ACS and the stable
plague [30]. The study results of this study showed that as
compared to the control group, the ratio of Th17 cells and
cytokines IL-17 of the ischemia group, non-ischemia group,
heart function Ⅲ–Ⅳ group, heart function Ⅰ–Ⅱ group, event
group and non-event group all increased signiﬁcantly while their
ratio of Treg cells and cytokines IL-10 decreased distinctly.
Besides, Th17/Treg and IL-17/IL-10 also increased obviously.
All differences showed statistical signiﬁcance (P < 0.05). The
results demonstrated that the balance of Th17/Treg shifted to-
wards Th17 in CHF. It is considered that the decrease of Treg
cells aggravates the ventricular remodeling and the impaired
immune tolerance causes pathological immune responses, which
eventually make the myocardial cells become attack targets. In
addition, the increase of Th17 exacerbates the severity of in-
ﬂammatory response, rejects the pathway of Treg cells, inhibits
the production of Treg cells and causes the decrease of Treg cells
[29].
The results of a further correlation analysis of the cytokines
secreted by various subsets of CD4 T cells, sensitive index of
heart failure BNP and heart function indexes LVEDd and LVEF
showed that IFN-g and IL-17 were signiﬁcantly positively
correlated with LVEDd and BNP, IL-4 and IL-10 were also
signiﬁcantly positively correlated with LVEF, but correlated
negatively with BNP, and IL-17 was negatively correlative with
LVEF. These cytokines can, to some degree, reﬂect the devel-
opment of the disease, which may have potential values on the
treatment and estimation of prognosis.
To sum up, after systematically analyzed the CD4+ T cell
subsets and their cytokines levels, it is concluded that there was
a correlation between CHF and the dysfunction of CD4+ T cells
showing immune activation phenomena of shifting from the
Th1/Th2 balance towards Th1 and from the Th17/Treg balance
towards Th17, and meanwhile the types, severity and prognosis
of the disease are involved.
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